Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Klebanoff Website

Christopher A. Klebanoff, M.D.

Selected Publications

1)  Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP.
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.
Nature. 498: 506-10, 2013.
[Journal]
2)  Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L.
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.
J. Clin. Invest. 123: 4479-88, 2013.
[Journal]
3)  Aoyama K, Saha A, Tolar J, Riddle MJ, Veenstra RG, Taylor PA, Blomhoff R, Panoskaltsis-Mortari A, Klebanoff CA, Socié G, Munn DH, Murphy WJ, Serody JS, Fulton LM, Teshima T, Chandraratna RA, Dmitrovsky E, Guo Y, Noelle RJ, Blazar BR.
Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.
Blood. 122: 2125-34, 2013.
[Journal]
4)  Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA, Ferreyra GA, Leonardi AJ, Borman ZA, Wang J, Palmer DC, Wilhelm C, Cai R, Sun J, Napoli JL, Danner RL, Gattinoni L, Belkaid Y, Restifo NP.
Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells.
J. Exp. Med. 210: 1961-76, 2013.
[Journal]
5)  Gattinoni L, Klebanoff CA, Restifo NP.
Paths to stemness: building the ultimate antitumour T cell.
Nat. Rev. Cancer. 12: 671-84, 2012.
[Journal]
6)  Klebanoff CA, Gattinoni L, Restifo NP.
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?.
J. Immunother. 35: 651-60, 2012.
[Journal]
7)  Klebanoff CA, Gattinoni L.
Stubborn Tregs limit T-cell therapy.
Blood. 120: 2352-4, 2012.
[Journal]
8)  Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP.
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Clin. Cancer Res. 17: 5343-52, 2011.
[Journal]
9)  Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P, Wang E, Schrump DS, Marincola FM, Restifo NP, Gattinoni L.
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells.
Nat. Immunol. 12: 1230-7, 2011.
[Journal]
10)  Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP.
Th17 cells are long lived and retain a stem cell-like molecular signature.
Immunity. 35: 972-85, 2011.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/7/2014.